Cargando…

Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study

To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Asamoah, Francis A., Yarney, Joel, Awasthi, Shivanshu, Vanderpuye, Verna, Dadzie, Mary A., Fink, Angelina, Naghavi, Arash O., Abrahams, Afua, Mensah, James E., Sasu, Evans, Tagoe, Samuel N., Dhillon, Jasreman, Johnstone, Peter A.S., Yamoah, Kosj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887629/
https://www.ncbi.nlm.nih.gov/pubmed/31584456
http://dx.doi.org/10.1097/COC.0000000000000589
_version_ 1783475060043939840
author Asamoah, Francis A.
Yarney, Joel
Awasthi, Shivanshu
Vanderpuye, Verna
Dadzie, Mary A.
Fink, Angelina
Naghavi, Arash O.
Abrahams, Afua
Mensah, James E.
Sasu, Evans
Tagoe, Samuel N.
Dhillon, Jasreman
Johnstone, Peter A.S.
Yamoah, Kosj
author_facet Asamoah, Francis A.
Yarney, Joel
Awasthi, Shivanshu
Vanderpuye, Verna
Dadzie, Mary A.
Fink, Angelina
Naghavi, Arash O.
Abrahams, Afua
Mensah, James E.
Sasu, Evans
Tagoe, Samuel N.
Dhillon, Jasreman
Johnstone, Peter A.S.
Yamoah, Kosj
author_sort Asamoah, Francis A.
collection PubMed
description To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable intermediate risk PCa patient subgroups; GM (173) and USM (814). Differences in baseline covariates and clinical characteristics between GM and USM were analyzed using χ(2) and Mann-Whitney test while Cox Proportional Hazards model was used to assess freedom from biochemical failure differences between the study groups. RESULTS: Median follow-up for this study was 40 months. GM were diagnosed at a younger median age (64 vs. 68 y, P<0.001) with heavier unfavorable intermediate risk disease burden (32.4% vs. 19.2%) compared with USM. Significant differences were identified in median external beam radiotherapy dose (72.4 vs. 78 Gy, P<0.001); brachytherapy utilization (49.7% vs. 80.6%, P<0.001) and androgen deprivation therapy for intermediate risk disease (48.4% vs. 21.0%, P<0.001) between GM and USM, respectively. GM with low risk and favorable intermediate risk PCa were at increased risk of biochemical recurrence compared with USM with adjusted hazard ratio: 5.15 (1.27 to 20.7), P=0.02 and 4.64 (1.20 to 17.92), P=0.02, respectively. CONCLUSIONS: Compared with USM, GM with low and favorable intermediate risk PCa may experience less durable disease control following standard treatment recommendations. Results suggest differences in radiation treatment and possible inherent differences between the 2 populations. This data will aid in developing research strategies to improve treatment outcomes in GM.
format Online
Article
Text
id pubmed-6887629
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-68876292020-01-22 Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study Asamoah, Francis A. Yarney, Joel Awasthi, Shivanshu Vanderpuye, Verna Dadzie, Mary A. Fink, Angelina Naghavi, Arash O. Abrahams, Afua Mensah, James E. Sasu, Evans Tagoe, Samuel N. Dhillon, Jasreman Johnstone, Peter A.S. Yamoah, Kosj Am J Clin Oncol Original Articles: Genitourinary To evaluate early-stage prostate cancer (PCa) radiotherapy treatment patterns and outcomes among Ghanaian men (GM) compared with US men (USM). MATERIALS AND METHODS: This retrospective study consists of 987 National Comprehensive Cancer Network low risk, favorable intermediate risk, and unfavorable intermediate risk PCa patient subgroups; GM (173) and USM (814). Differences in baseline covariates and clinical characteristics between GM and USM were analyzed using χ(2) and Mann-Whitney test while Cox Proportional Hazards model was used to assess freedom from biochemical failure differences between the study groups. RESULTS: Median follow-up for this study was 40 months. GM were diagnosed at a younger median age (64 vs. 68 y, P<0.001) with heavier unfavorable intermediate risk disease burden (32.4% vs. 19.2%) compared with USM. Significant differences were identified in median external beam radiotherapy dose (72.4 vs. 78 Gy, P<0.001); brachytherapy utilization (49.7% vs. 80.6%, P<0.001) and androgen deprivation therapy for intermediate risk disease (48.4% vs. 21.0%, P<0.001) between GM and USM, respectively. GM with low risk and favorable intermediate risk PCa were at increased risk of biochemical recurrence compared with USM with adjusted hazard ratio: 5.15 (1.27 to 20.7), P=0.02 and 4.64 (1.20 to 17.92), P=0.02, respectively. CONCLUSIONS: Compared with USM, GM with low and favorable intermediate risk PCa may experience less durable disease control following standard treatment recommendations. Results suggest differences in radiation treatment and possible inherent differences between the 2 populations. This data will aid in developing research strategies to improve treatment outcomes in GM. Lippincott Williams & Wilkins 2019-12 2019-10-03 /pmc/articles/PMC6887629/ /pubmed/31584456 http://dx.doi.org/10.1097/COC.0000000000000589 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles: Genitourinary
Asamoah, Francis A.
Yarney, Joel
Awasthi, Shivanshu
Vanderpuye, Verna
Dadzie, Mary A.
Fink, Angelina
Naghavi, Arash O.
Abrahams, Afua
Mensah, James E.
Sasu, Evans
Tagoe, Samuel N.
Dhillon, Jasreman
Johnstone, Peter A.S.
Yamoah, Kosj
Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title_full Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title_fullStr Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title_full_unstemmed Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title_short Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
title_sort definitive radiation treatment patterns and outcomes for low and intermediate risk prostate cancer patients: a cross-continental comparative study
topic Original Articles: Genitourinary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887629/
https://www.ncbi.nlm.nih.gov/pubmed/31584456
http://dx.doi.org/10.1097/COC.0000000000000589
work_keys_str_mv AT asamoahfrancisa definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT yarneyjoel definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT awasthishivanshu definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT vanderpuyeverna definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT dadziemarya definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT finkangelina definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT naghaviarasho definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT abrahamsafua definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT mensahjamese definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT sasuevans definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT tagoesamueln definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT dhillonjasreman definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT johnstonepeteras definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy
AT yamoahkosj definitiveradiationtreatmentpatternsandoutcomesforlowandintermediateriskprostatecancerpatientsacrosscontinentalcomparativestudy